Search PubMed⌕ Search

Biomedical subjects

E Gillespie

Publications and source records attributed to E Gillespie.

At least 37 records · Page 2Linked to original sources
PubMed1980

Effects of colchicine, vinblastine, griseofulvin and deuterium oxide upon phospholipid metabolism in concanavalin A-stimulated lymphocytes.

Colchicine has previously been shown to inhibit the incorporation of [3H]-inositol into phosphatidylinositol in lymphocytes stimulated with concanavalin A. In the present study other agents known to interact with tubulin or affect microtubule assembly/disassembly were examined for effects on 32PO4 incorporation into phospholipids and [3H]inositol incorporation into phosphatidylinositol. Vinblastine inhibited the enhanced incorporation caused by concanavalin A of either [3H]inositol or 32PO4 into phosphatidylinositol and phosphatidic acid. It had no effect on basal incorporation of 32PO4 and enhanced basal incorporation of [3H]inositol into nonstimulated lymphocytes. Griseofulvin at concentrations up to 10(-3) M had no effect on uptake of either label. Deuterium oxide had effects similar to vinblastine in that basal incorporation of both labels was enhanced while inhibition of the concanavalin A stimulated incorporation was observed. These results suggest an action of these various compounds other than or in addition to their known effects on cytoplasmic microtubules.

Colchicine↗
PubMed1978

IgE-induced changes in human basophil cyclic AMP levels.

We studied a unique patient with 77% basophils, not different from normal by a number of criteria, in order to measure the changes in cyclic AMP level associated with IgE-mediated histamine release. In accordance with previous hypothesis and circumstantial evidence, anti-IgE challenge led to a significant fall in the cyclic AMP level which preceded histamine release.

Basophils↗
PubMed1978

Concanavalin A increases glyoxalase enzyme activities in polymorphonuclear leukocytes and lymphocytes.

Glyoxalase I converts methylglyoxal and glutathione to S-lactoylglutathione and glyoxalase II converts this compound to D-lactic acid, regenerating glutathione in the process. A recent study from my laboratory has provided evidence that S-lactoylglutathione modulates microtubule assembly in vitro whereas concanavalin A (Con A) has been shown to increase microtubule occurrence in polymorphonuclear leukocytes (PMN). The present report describes the dose-dependent activation by Con A of both glyoxalase I and II in PMN and lymphocytes. In nine experiments with PMN, Con A (100 microgram/ml) increased glyoxalase I and II activities by 19 +/- 8% and 12 +/- 10% (mean +/- S.D.). In 17 experiments with lymphocytes, activation of the two enzymes by 10 microgram/ml Con A was 30 +/- 14% and 28 +/- 8%. Changes occurred after a 1-min incubation with Con A and persisted for at least 60 min. Since both enzyme activities are increased it is not clear if S-lactoylglutathione levels are increased or decreased but presumably they change. The present findings are compatible with the hypothesis that Con A increases microtubule occurrence in PMN by affecting the glyoxalase enzymes. They also represent a newly described early biochemical change caused by Con A in lymphocytes.

Concanavalin A↗
PubMed1975

The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine.

Antigen-induced, IgE-mediated release of histamine from human basophiles is an in vitro model of allergic reacttions; it is blocked by extracellular histamine, presumably as a result of its ability to increase adenosine 3',5'-monophosphate (cyclic AMP) levels. The H1 antihistamines do not antagonize these effects of histamine but at approximately equal to 1 mM cause histamine release and at approximately equal to 0.1mM inhibit antigen-induced histamine release. The phenothiazine antihistamines are 10-30 fold more potent inhibitors than the rest; other tricyclic antidepressant drugs share this activity. The mechanism of this inhibition, which occurs in both the 1 degree and 2 degree stages of histamine release, is not known but it is not due to partial agonist activity since the anti-H1 drugs cause a significant fall in cyclic AMP levels. The anti-anaphylactic effects of the H1 antagonists probably play no therapeutic role but we suggest that drugs structurally similar to the phenothiazine antihistamines should be developed for clinical testing. The H2 antihistamines block histamine-induced inhibition of histamine release and the increase in cyclic AMP levels, but neither cause nor inhibit histamine release. The K-B values for the anti-H2 drugs (burimamide approximately equal to 5 muM); metiamide approximately equal to 0.5muM); are similar to those described for other H2 receptors.

Animals↗
PubMed1975

Histamine release from human leukocytes: relationships between cyclic nucleotide, calcium, and antigen concentrations.

The antigen-induced IgE-mediated release of histamine from human basophils has previously been shown to require calcium, to be inhibited by agents which raise cyclic AMP levels and by high antigen levels, and to be unaffected by cyclic GMP. The interrelationship between these phenomena has been studied. The major findings are: 1) in the region of antigen-excess inhibition dibutyryl cyclic AMP potentiates release; 2) antigen-excess inhibition is seen at lower antigen concentrations when the calcium concentration is reduced from 0.6 to 0.1 mM; and 3) cyclic GMP modestly potentiates release when the calcium concentration is 0.1 mM.

Antibodies↗
PubMed1973

In vivo suppression of the immune response to alloantigen by cholera enterotoxin.

The immune response of C57BL/6 mice to allogeneic (DBA/2) mastocytoma cell suspensions was profoundly suppressed by intraperitoneal administration of 1 mug cholera enterotoxin 4 days after antigenic stimulation. The immune response assayed 11 days after antigen showed decreased cytolytically active thymusderived (T) lymphocytes and markedly depressed serumagglutinating titers. A comparable suppression of the immune response to skin allografts (DBA/2-->C57BL/6) was also effected by cholera toxin administration, although there was no prolongation of allograft survival. The mechanism of the immune suppression is apparently related to the known adenylate cyclase stimulatory activities of choleragen.

Agglutination Tests↗